product name Myricitrin
Description: Myricitrin, a flavonoid compound isolated from the root bark of Myrica cerifera, which exerts antinociceptive effects. Myricitrin produces pronounced antinociception against chemical and mechanical models of pain in rodents via preventing the protein kinase C (PKC) alpha and PKC epsilon activation by phorbol myristate acetate (PMA). Another study proves that opening of voltage- and small-conductance calcium-gated K(+) channels and reduction of calcium influx leads to the antinociceptive of myricitrin.
References: J Pharmacol Exp Ther. 2006 Feb;316(2):789-96; Eur J Pharmacol. 2007 Jul 19;567(3):198-205.
464.38
Formula
C21H20O12
CAS No.
17912-87-7
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 93 mg/mL (200.3 mM)
Water: <1 mg/mL
Ethanol: 1 mg/mL (2.1 mM)
Solubility (In vivo)
Synonyms
Myricitrine
other peoduct :
| In Vitro |
In vitro activity: Myricitrin, a flavonoid compound isolated from the root bark of Myrica cerifera, which exerts antinociceptive effect. Myricitrin produces pronounced antinociception against chemical and mechanical models of pain in rodents via preventing the protein kinase C (PKC) alpha and PKC epsilon activation by phorbol myristate acetate (PMA). Another study proves that opening of voltage- and small-conductance calcium-gated K(+) channels and reduction of calcium influx leads to the antinociceptive of myricitrin. Myricitrin also decreases H2O2-induced apoptosis in vascular endothelial cells via inhibition of p53 gene expression, activation of caspase-3 and the MAPK signaling pathway, and alteration of the patterns of pro-apoptotic and anti-apoptotic gene expression. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | In mice, myricitrin (i.p. 10 mg/kg or 30 mg/kg) blocks apomorphine-induced stereotypy and climbing, and increases hindlimb retraction time (HRT). |
| Animal model | Male adult Swiss albino mice |
| Formulation & Dosage | Dissolved in Tween 80 followed by saline; 10, 30 mg/kg; i.p. injection |
| References | J Pharmacol Exp Ther. 2006 Feb;316(2):789-96; Eur J Pharmacol. 2007 Jul 19;567(3):198-205; Prog Neuropsychopharmacol Biol Psychiatry. 2011 Aug 15;35(7):1636-44. |
